These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 21291395)

  • 1. Stereochemistry at the forefront in the design and discovery of novel anti-tuberculosis agents.
    Huang Q; He R; Kozikowski AP
    Curr Top Med Chem; 2011; 11(7):810-8. PubMed ID: 21291395
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Trends in the discovery of new drugs for Mycobacterium tuberculosis therapy with a glance at resistance.
    Lohrasbi V; Talebi M; Bialvaei AZ; Fattorini L; Drancourt M; Heidary M; Darban-Sarokhalil D
    Tuberculosis (Edinb); 2018 Mar; 109():17-27. PubMed ID: 29559117
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plan to combat extensively drug-resistant tuberculosis: recommendations of the Federal Tuberculosis Task Force.
    Centers for Disease Control and Prevention (CDC)
    MMWR Recomm Rep; 2009 Feb; 58(RR-3):1-43. PubMed ID: 19214162
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-tuberculosis lead molecules from natural products targeting Mycobacterium tuberculosis ClpC1.
    Lee H; Suh JW
    J Ind Microbiol Biotechnol; 2016 Mar; 43(2-3):205-12. PubMed ID: 26586403
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery of antitubercular 2,4-diphenyl-1H-imidazoles from chemical library repositioning and rational design.
    Pieroni M; Wan B; Zuliani V; Franzblau SG; Costantino G; Rivara M
    Eur J Med Chem; 2015 Jul; 100():44-9. PubMed ID: 26071857
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Coumarin hybrid derivatives as promising leads to treat tuberculosis: Recent developments and critical aspects of structural design to exhibit anti-tubercular activity.
    Reddy DS; Kongot M; Kumar A
    Tuberculosis (Edinb); 2021 Mar; 127():102050. PubMed ID: 33540334
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New treatment options for multidrug-resistant tuberculosis.
    Field SK; Fisher D; Jarand JM; Cowie RL
    Ther Adv Respir Dis; 2012 Oct; 6(5):255-68. PubMed ID: 22763676
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recent progress in the drug development of coumarin derivatives as potent antituberculosis agents.
    Keri RS; Sasidhar BS; Nagaraja BM; Santos MA
    Eur J Med Chem; 2015 Jul; 100():257-69. PubMed ID: 26112067
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Editorial: Current status and perspective on drug targets in tubercle bacilli and drug design of antituberculous agents based on structure-activity relationship.
    Tomioka H
    Curr Pharm Des; 2014; 20(27):4305-6. PubMed ID: 24245755
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Delamanid: From discovery to its use for pulmonary multidrug-resistant tuberculosis (MDR-TB).
    Liu Y; Matsumoto M; Ishida H; Ohguro K; Yoshitake M; Gupta R; Geiter L; Hafkin J
    Tuberculosis (Edinb); 2018 Jul; 111():20-30. PubMed ID: 30029909
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New tuberculostatic agents targeting nucleic acid biosynthesis: drug design using QSAR approaches.
    Bueno RV; Braga RC; Segretti ND; Ferreira EI; Trossini GH; Andrade CH
    Curr Pharm Des; 2014; 20(27):4474-85. PubMed ID: 24245758
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multidrug-resistant and extensively drug-resistant tuberculosis in the West. Europe and United States: epidemiology, surveillance, and control.
    Migliori GB; D'Arcy Richardson M; Sotgiu G; Lange C
    Clin Chest Med; 2009 Dec; 30(4):637-65, vii. PubMed ID: 19925959
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Recent progress in mycobacteriology].
    Okada M; Kobayashi K
    Kekkaku; 2007 Oct; 82(10):783-99. PubMed ID: 18018602
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design, synthesis and investigation on the structure-activity relationships of N-substituted 2-aminothiazole derivatives as antitubercular agents.
    Pieroni M; Wan B; Cho S; Franzblau SG; Costantino G
    Eur J Med Chem; 2014 Jan; 72():26-34. PubMed ID: 24333612
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Old antibiotics for emerging multidrug-resistant/extensively drug-resistant tuberculosis (MDR/XDR-TB).
    Brouqui P; Quenard F; Drancourt M
    Int J Antimicrob Agents; 2017 May; 49(5):554-557. PubMed ID: 28336312
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Isoniazid derivatives and their anti-tubercular activity.
    Hu YQ; Zhang S; Zhao F; Gao C; Feng LS; Lv ZS; Xu Z; Wu X
    Eur J Med Chem; 2017 Jun; 133():255-267. PubMed ID: 28390957
    [TBL] [Abstract][Full Text] [Related]  

  • 18. DFT based QSAR/QSPR models in the development of novel anti-tuberculosis drugs targeting Mycobacterium tuberculosis.
    Rajkhowa S; Deka RC
    Curr Pharm Des; 2014; 20(27):4455-73. PubMed ID: 24245759
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Management of drug resistantTB in patients with HIV co-infection.
    Pontali E; Sotgiu G; Centis R; D'Ambrosio L; Spanevello A; Migliori GB
    Expert Opin Pharmacother; 2015; 16(18):2737-50. PubMed ID: 26478945
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Promising candidates in clinical trials against multidrug-resistant tuberculosis (MDR-TB) based on natural products.
    de Souza MV
    Fitoterapia; 2009 Dec; 80(8):453-60. PubMed ID: 19698768
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.